TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
MedPage Today published a roundup of comments from clinicians and researchers on medical developments reported during the week of October 25, 2026. The topics ranged from dengue outbreaks and questions about dupilumab exposure during pregnancy to menopause symptoms, advance care planning and early-stage research in Parkinson’s disease.
MedPage Today published a weekly roundup on October 25 featuring comments from clinicians and researchers on medical stories reported during the week, including dengue outbreaks in Florida, research on menopause symptoms and early findings involving Parkinson’s disease. The collection offers brief reactions rather than a single new study or policy announcement, and several of the topics remain open research questions.
The roundup’s public-health item concerned dengue. Adam Waickman, a researcher at SUNY Upstate Medical University, said, “The cat is out of the bag,” while discussing large outbreaks in Florida and warning of possible further spread across the United States. The quotation conveys concern, but the roundup does not provide case counts, locations of specific outbreaks, or a forecast establishing how far the virus will spread.
Other comments addressed questions about treatment and risk. Christina Chambers of the University of California San Diego said it remains “an open question” whether exposure to dupilumab, sold as Dupixent, early in life could reduce a child’s later risk of atopic conditions. The roundup says data indicated exposure during pregnancy appeared safe; it does not supply study details or establish that the medicine prevents those conditions.
The collection also included comments on an incorrect multiple sclerosis diagnosis discussed by Cleveland Clinic neurologist Marisa McGinley; an exceptionally rare case in which an infant later was found to have a second colon; and a meta-analysis on non-hormonal medicines and sleep disturbances during menopause. It cited research on a video decision-support tool for advance care planning among people nearing kidney failure, as well as a small trial linking psilocybin use in patients with Parkinson’s disease to lower markers of systemic inflammation and mitochondrial stress. These are separate reports, with different evidence bases and limitations.
Several Findings, Different Evidence Levels
The roundup brings together issues with practical relevance for patients and clinicians, but its format should not blur the distinction between a researcher’s interpretation and a settled result. Dengue spread is a public-health concern, while the comments on dupilumab, menopause treatments and psilocybin point to research findings that need to be read in light of their methods and scope.
For readers, the key point is that the seven quotations do not amount to one unified medical conclusion. A meta-analysis, a small clinical trial, a case report and a discussion of a diagnostic error provide different kinds of evidence. The roundup’s brief excerpts can identify topics to follow, but they cannot replace the underlying studies or reporting for details about participants, effect sizes, risks and limitations.
The comments also highlight decisions that extend beyond treatment results. The advance care planning research, as described in the roundup, focused on documentation of patients’ preferences. That matters because care teams need to understand what patients value, particularly as serious illness progresses. The quoted researcher’s statement describes a goal for care records, not proof that the tool improves health outcomes.
EPA registered mosquito repellent for dengue prevention
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
The Stories Behind the Quotes
MedPage Today presented the items as “quotable quotes heard by MedPage Today’s reporters” in a two-minute weekly opinion roundup. The source lists comments from specialists and researchers tied to several distinct subjects; it is not a comprehensive account of medical developments from the week. The material provided does not include publication dates for the underlying studies or links to their full methods and results.
Some quotations refer to specific developments. Waickman was discussing Florida dengue outbreaks. Chambers was commenting on possible long-term effects of early-life dupilumab exposure, alongside data described as showing apparent safety during pregnancy. JoAnn Manson of Harvard Medical School characterized a meta-analysis on non-hormonal menopause drugs as good news for women, while the source summary says the analysis found the drugs could ease sleep disturbances.
The other items range from a diagnostic error involving actress Christina Applegate to an exceptionally rare infant case and research into advance care planning. The final research item concerns a small trial of psilocybin in people with Parkinson’s disease. The source reports a link to lower biological markers, not evidence that psilocybin treats Parkinson’s disease or improves symptoms.
““This is good news for women.””
— JoAnn Manson, MD, MPH, DrPH, of Harvard Medical School
As an affiliate, we earn on qualifying purchases.
Study Details Still Matter
The roundup does not provide enough detail to independently assess the studies it mentions. It gives no dengue case counts or geographic breakdown, and the warning about further U.S. spread is attributed to Waickman rather than presented with a forecast or public-health estimate.
For the dupilumab item, the source does not identify the study design, number of pregnancies or children followed, or the length of follow-up. It also does not establish that early exposure reduces later atopic conditions. The menopause summary does not name the drugs, quantify changes in sleep, or describe the populations included in the meta-analysis.
The psilocybin finding is described as coming from a small trial and concerns biological markers. The source does not report participant numbers, the size or duration of any change, or whether the markers corresponded to clinical improvement. Details of the advance care planning tool’s effect and the rare infant case are also limited in the supplied account.
As an affiliate, we earn on qualifying purchases.
Follow the Underlying Reports
The next step for readers seeking more than the roundup’s brief takeaways is to consult the underlying reports and studies. Those materials would clarify the methods, participant groups, measured outcomes and limitations behind the comments. For dengue, updated local and public-health reporting would be needed to establish the scale and location of outbreaks and whether spread is occurring elsewhere.
Research on pregnancy exposure to dupilumab and long-term atopic risk would need to be assessed as follow-up data become available; the quotation does not announce a final finding. The menopause analysis and Parkinson’s trial also require their full results to judge how substantial the reported effects were and what further study is warranted. The weekly roundup itself sets no timetable for additional findings or announcements.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the actual news in this roundup?
MedPage Today published a weekly collection of medical quotes on October 25, 2026. It summarizes comments about several separate stories rather than reporting one new clinical development.
Did the roundup confirm that dengue is spreading across the United States?
No. It reports that Adam Waickman discussed large outbreaks in Florida and warned of possible further spread. The supplied material does not provide case counts or confirm spread to other parts of the country.
Does the source say dupilumab prevents atopic conditions in children?
No. Chambers described that possibility as an open question. The roundup says data showed pregnancy exposure appeared safe, but it does not establish prevention or provide enough study detail to assess the finding.
What did the menopause research find?
The roundup says a meta-analysis found that non-hormonal menopause drugs could ease sleep disturbances. It does not identify the medicines or provide effect sizes, so the full analysis is needed for details.
Does the psilocybin trial show that it treats Parkinson’s disease?
No such conclusion is reported. The roundup describes a small trial linking psilocybin with reduced markers of systemic inflammation and mitochondrial stress. It does not say the trial showed symptom improvement or established a treatment.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
